Drug Development Pharma - November 25, 2013
US approval of Simeprevir
Medivir has received US approval of its Simeprevir for the treatmeant of hepatitis C. On Friday 22 Medivir and Janssen’s drug candidate Simeprevir was approved for the US market by the Food and Drug Administration (FDA). The product will be approved for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with […]
Drug Development Pharma - November 25, 2013
European approval for Lundbeck and Otsuka
Lundbeck and Otsuka Pharmaceutical Co., Ltd. (Otsuka) have announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole). Abilify Maintena is an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. “Studies have shown that the early use of long-acting injectables can prevent a person with schizophrenia […]
MedTech Business - November 25, 2013
Niox Mino gets approval in Japan
Swedish Aerocrine AB has announced that the Japanese authority has approved the FeNO measuring device Niox Mino. On 28 of March 2013 the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) decided to grant the 2008 version of the Niox Mino marketing approval in Japan. As Aerocrine introduced a new version in 2010 of the product, […]
Uncategorized - November 22, 2013
New network to try alternatives to animal testing
SP Technical Research Institute of Sweden is joining EU-NETVAL in a new European network of laboratories to validate alternative methods to animal testing. SP will be the only Swedish laboratory to join EU-NETVAL. The network is part of the European Union’s work to replace animal testing. As a member SP can contribute to reliable methods being […]
Uncategorized - November 21, 2013
New findings on genes behind asthma attacks
An international team spearheaded by researchers from the Faculty of Health and Medical Sciences at the University of Copenhagen have identified the genes that put some children at risk of experiencing severe asthma attacks. “Our results show that asthma attacks requiring young children to be hospitalised are usually genetically related. Genes play a far greater role in […]
Agreement - November 21, 2013
Biogaia signs exclusive agreement in Brazil
Biogaia has signed a long-term agreement with Aché for the exclusive rights to sell Biogaia’s probiotic drops and tablets in Brazil. According to Biogaia the products will be co-branded with expected launch in mid-2014. ”We are pleased to engage in an enduring collaboration with BioGaia, enabling the launch of relevant products in the Brazilian market. […]
